Pelitinib (EKB-569)

Pelitinib is a pan-ErbB tyrosine kinase inhibitor with potential anticancer activity. Pelitinib irreversibly binds covalently to epidermal growth factor receptors (EGFR) ErbB-1, -2 and -4, thereby inhibiting receptor phosphorylation and signal transduction and resulting in apoptosis and suppression of proliferation in tumor cells that overexpress these receptors.